Bristol-Myers Squibb has declared a quarterly cash dividend of $0.63 per share, payable to shareholders of record in early August 2026. The pharmaceutical giant maintains one of the more reliable dividend tracks among large-cap healthcare names.
The setup
Bristol-Myers Squibb declared its quarterly dividend on July 2, 2026. The ex-dividend date is set for August 3, 2026, with payment following shortly after the record date. The $0.63 per share quarterly rate annualizes to $2.52 per share.
The New York-based company is a leading biopharmaceutical firm with a portfolio spanning oncology, immunology, cardiovascular, and fibrosis therapies. Key products include Eliquis, Opdivo, and Revlimid. Revenue stability from its blockbuster drug lineup supports the dividend policy.
Key numbers
| Metric | Value |
|---|---|
| Quarterly dividend | $0.63 per share |
| Annualized dividend | $2.52 per share |
| Indicated yield | ~4.3% |
| Declaration date | July 2, 2026 |
| Ex-dividend date | August 3, 2026 |
| Dividend type | Quarterly cash |
| Ticker | BMY (NYSE) |
What the dividend means for income investors
A $0.63 quarterly payout provides meaningful income for healthcare-sector exposure. An investor holding 400 shares of Bristol-Myers Squibb would collect $252 per quarter, or $1,008 annually, before taxes. That income level is attractive for retirees seeking yield from a mature pharmaceutical name.
The indicated yield of approximately 4.3 percent places Bristol-Myers among the higher-yielding large-cap healthcare stocks. The yield reflects both the company’s generous payout and some investor caution about patent cliffs and pipeline execution.
Per-$100K income comparison
| Stock | Approx. Price | Shares per $100K | Quarterly Income | Annual Income |
|---|---|---|---|---|
| Bristol-Myers (BMY) | ~$59 | ~1,695 | ~$1,068 | ~$4,272 |
| Pfizer (PFE) | ~$30 | ~3,333 | ~$1,433 | ~$5,732 |
| Johnson & Johnson (JNJ) | ~$165 | ~606 | ~$752 | ~$3,008 |
The per-$100K comparison shows Bristol-Myers generates strong absolute income relative to invested capital. Pfizer produces more per $100K but carries higher uncertainty from post-pandemic revenue normalization. Johnson & Johnson offers lower absolute income but compensates with 60+ years of consecutive dividend increases.
Peer comparison
| Company | Ticker | Quarterly Div. | Annual Yield (approx.) |
|---|---|---|---|
| Bristol-Myers Squibb | BMY | $0.63 | ~4.3% |
| Pfizer | PFE | ~$0.43 | ~5.8% |
| Johnson & Johnson | JNJ | ~$1.24 | ~3.0% |
| AbbVie | ABBV | ~$1.63 | ~3.4% |
Bristol-Myers offers a higher yield than Johnson & Johnson and AbbVie but trails Pfizer. Pfizer’s elevated yield reflects post-COVID revenue declines and a depressed stock price. Johnson & Johnson trades at a lower yield but offers greater dividend longevity as a Dividend King with 60+ consecutive years of increases.
Risks to watch
Patent expirations remain the dominant risk for pharmaceutical dividend stocks. Bristol-Myers faces eventual generic competition for key therapies. The company’s ability to replace lost revenue through pipeline approvals and business development will determine whether the dividend can grow or merely hold steady.
Regulatory scrutiny of drug pricing also poses a headwind. Medicare negotiation authority under the Inflation Reduction Act could pressure pricing power for select products. Investors should monitor pipeline updates and FDA approval timelines for new molecular entities.
Common mistakes income investors make
Chasing yield without understanding the business behind it is a frequent error. Pfizer’s 5.8% yield looks attractive on paper, but the company’s revenue base has contracted sharply since peak COVID demand. Bristol-Myers’ 4.3% yield sits on a more stable earnings foundation, though it is not immune to pipeline setbacks.
Another mistake is failing to diversify across healthcare subsectors. Concentrating in Big Pharma alone ignores the growth potential and income opportunities in medical devices, health insurers, and biotechnology. A balanced healthcare allocation reduces single-product risk while maintaining yield.
Bottom line
Bristol-Myers Squibb’s $0.63 quarterly dividend offers an attractive yield for income investors comfortable with pharmaceutical-sector risks. The company’s cash generation from established therapies supports the current payout, though long-term dividend growth depends on pipeline success. BMY remains a viable income holding for diversified healthcare exposure.
Stay ahead with our weekly newsletter
Get stock picks, market analysis, and strategy updates delivered to your inbox every week.
Subscribe to AlphaBetaStock’s free newsletter for daily market insights.
